Formulation And Evaluation of Solid Lipid Nanoparticles Of Tropicamide

Abstract

Solid lipid nanoparticles (SLNs) represent a significant advancement in the field of nanotechnology, offering a versatile and efficient platform for drug delivery and biomedical applications. These nanoparticles are composed of biocompatible lipids that remain solid at room and body temperatures, allowing them to encapsulate both hydrophilic and hydrophobic therapeutic agents effectively. Their nanoscale dimensions provide unique advantages, such as enhanced drug stability, improved bioavailability of poorly water-soluble drugs, and controlled or targeted release profiles. SLNs can be synthesised using various methods, including high-pressure homogenisation, solvent emulsification, ultrasonication, and double emulsion techniques. These approaches produce uniform particles with customisable surface properties, enabling functionalisation for ligand-mediated targeting or tailored pharmacokinetics. The lipid matrix not only improves drug solubility but also reduces the risk of toxicity, as the components are generally recognized as safe and are often derived from physiological sources. Applications of SLN technology extend across multiple routes of administration—oral, parenteral, topical, pulmonary, and more—facilitating their integration into therapies for diseases requiring precision in drug delivery. They have shown promise in advancing the delivery of anticancer drugs, vaccines, genetic materials, and cosmetic agents. The continued development of SLNs is opening new possibilities for controlled, site-specific therapy and holds substantial potential for the future of nanomedicine.